Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization

Neuro-Oncology

Volumn 18, Issue 6, 2016, Pages 797-806

  Stafford, Jason H ^a   Hirai, Takahisa ^a,b   Deng, Lei ^a   Chernikova, Sophia B ^a   Urata, Kimiko ^a   West, Brian L ^c   Brown, J Martin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JUNTENDO UNIVERSITY   (Japan)

^c PLEXXIKON INC   (United States)

Author keywords

angiogenesis; CSF 1; glioblastoma; macrophages; radiation

Indexed keywords

CD11B ANTIGEN; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; PLX 3397; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; COLONY STIMULATING FACTOR 1; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BRAIN RADIATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIZING RADIATION; MONOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CYTOLOGY; DRUG EFFECTS; MACROPHAGE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; MONOCYTES; PROTEIN KINASE INHIBITORS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION;

EID: 84975154682     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov272     Document Type: Article

References (45)

1. Lim SK, Llaguno SR, McKay RM, et al. Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Rep. 2011;44(3):158-164.
2. Takano S. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol. 2012;29(2):73-86.
3. Hadziahmetovic M, Shirai K, Chakravarti A. Recent advancements in multimodality treatment of gliomas. Future Oncol. 2011;7(10): 1169-1183.
4. Beal K, Abrey L, Gutin P. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol. 2011;6(1):2.
5. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20(6):1635-1642.
6. De Palma M, Lewis Claire E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23(3):277-286.
7. Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120(3):694-705.
8. Liu S-C, Alomran R, Chernikova SB, et al. Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neurooncol. 2014;16(1):21-28.
9. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009;9(4):259-270.
10. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12(4):253-268.
11. Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012;119(8):1810-1820.
12. Lin EY, Nguyen AV, Russell RG, et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193(6):727-740.
13. Pyonteck SM, Gadea BB,Wang HW, et al. Deficiency of themacrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development. Oncogene. 2012;31(11):1459-1467.
14. Abraham D, Zins K, Sioud M, et al. Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma. Int J Cancer. 2010;126(6):1339-1352.
15. Carlson BL, Pokorny JL, Schroeder MA, et al. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc in Pharmacol. 2011;52:14.16:14.16.1-14.16.23.
16. Ozawa T, James CD. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp. 2010;(41):e1986. doi:10.3791/1986.
17. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101-1108.
18. Lin H, Lee E, Hestir K, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320(5877):807-811.
19. Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol. 1993;151(5):2399-2408.
20. Sunderkötter C, Nikolic T, Dillon MJ, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol. 2004;172(7):4410-4417.
21. Movahedi K, Laoui D, Gysemans C, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70(14):5728-5739.
22. Yona S, Kim K-W, Wolf Y, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38(1):79-91.
23. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423-1437.
24. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889-896.
25. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677-686.
26. Mantovani A, Biswas SK, Galdiero MR, et al. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013; 229(2):176-185.
27. Russell JS, Brown JM. The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front in Physiol. 2014;(13). doi: 10.1186/1476-4598-13-177.
28. Kozin SV, Kamoun WS, Huang Y, et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 2010;70(14):5679-5685.
29. Xu J, Escamilla J, Mok S, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013;73(9): 2782-2794.
30. DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54-67.
31. Wang JM, Griffin JD, Rambaldi A, et al. Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol. 1988;141(2):575-579.
32. Webb SE, Pollard JW, Jones GE. Direct observation and quantification of macrophage chemoattraction to the growth factor CSF-1. J Cell Sci. 1996;109(4):793-803.
33. Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264-1272.
34. León B, López-Bravo M, Ardavn C. Monocyte-derived dendritic cells. Semin Immunol. 2005;17(4):313-318.
35. León B, Martnez del Hoyo G, Parrillas V, et al. Dendritic cell differentiation potential of mouse monocytes: monocytes represent immediate precursors of CD82 and CD8+ splenic dendritic cells. Blood. 2004;103(7):2668-2676.
36. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327(5966): 656-661.
37. Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177(10):7303-7311.
38. Hashimoto D, Miller J, Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity. 2011;35(3):323-335.
39. Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057-5069.
40. Mok S, Koya RC, Tsui C, et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014;74(1):153-161.
41. Priceman SJ, Sung JL, Shaposhnik Z, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010;115(7):1461-1471.
42. Eubank TD, Galloway M, Montague CM, et al. M-CSF Induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol. 2003;171(5): 2637-2643.
43. Avraham-Davidi I, Yona S, Grunewald M, et al. On-site education of VEGF-recruited monocytes improves their performance as angiogenic and arteriogenic accessory cells. J Exp Med. 2013; 210(12):2611-2625.
44. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317(5838):666-670.
45. Carlin Leo M, Stamatiades Efstathios G, Auffray C, et al. Nr4a1-dependent Ly6C low monocytes monitor endothelial cells and orchestrate their disposal. Cell. 2013;153(2):362-375.